data stringlengths 254 8.94k | criteria stringlengths 0 16.5k | __index_level_0__ int64 0 45.1k |
|---|---|---|
Study Objectives
Study PT-112-102, a multicenter, open-label dose-finding and pharmacokinetic study of PT-112 in patients with relapsed or refractory multiple myeloma.
This is designed as a two-part study. In the first part of the study, cohorts of three patients (expanded to six patients in the event of a dose-limiti... | Key Inclusion Criteria:
1. Previously diagnosed with MM requiring treatment based on IMWG diagnostic criteria;
2. Relapsed or refractory MM after adequate exposure to and therapeutic response (following IMWG response criteria) to at least one line of treatment with one or more active agents, including alkylating drugs... | 4,191 |
Study Objectives
The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chidamide in a range of doses combined with CHOP in fixed dose in patients with newly diagnosed peripheral T-cell lymphoma.
Conditions: Peripheral T-cell Lymphoma
Intervention / Treatment:
DRUG: Chida... | Inclusion Criteria:
1. Male and female aged 18-65 years old;
2. Histopathologically confirmed Peripheral T -cell Lymphoma (PTCL) including:
* PTCL-unspecified;
* Angioimmunoblastic T-cell lymphoma;
* Anaplastic large cell lymphoma, ALK positive or negative;
* Subcutaneous panniculitis T-cell lymphoma;
... | 22,020 |
Study Objectives
Evaluation of maintenance BCG immunotherapy (dose 27 mg) in superficial bladder tumors. Two randomized arms (every 3 or 6 months) will be studied for a population of 300 patients.
Conditions: Bladder Cancer
Intervention / Treatment:
BIOLOGICAL: bladder tumor recurrence
Location: France
Study Design... | Inclusion Criteria:
* Ta and T1 bladder tumors
Exclusion Criteria:
* BCG contra-indications | 13,842 |
Study Objectives
The purpose of this study is to assess in a prospective multicentric study (Phase III) the introduction of a monoclonal antibody directed against B-cells associated with a standard therapy including chemotherapy and alpha-interferon in first line treatment of patients with a large tumor burden follicul... | Inclusion Criteria:
* Histologically confirmed follicular lymphoma with a biopsy performed in the last 3 months
* Patients previously untreated.
* Patients with at least one of the following symptoms requiring initiation of treatment:
* Bulky disease at study entry according to the Groupe d'Etudes Lymphomes Follicu... | 32,012 |
Study Objectives
The research aims to the primary hepatic carcinoma patients whose diameter of the single tumor is equal or less than 5cm.By supervising the changes of liver function, Child-Pugh score, ICG-R15 value, secondary reaction, incidence rate of RILD during and after the radiotherapy, meanwhile combining the o... | Inclusion Criteria:
* The participants are from 30 to 80 years of age, without gender restriction
* With the hepatopathy background, the diagnosis of primary hepatic carcinoma is confirmed by image examination and laboratory test(the diagnosis criteria is according to the primary hepatic carcinoma rule of diagnosis an... | 31,874 |
Study Objectives
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of combining irinotecan with cytarabine in treating patients who have refr... | DISEASE CHARACTERISTICS:
* Histologically confirmed acute myeloid leukemia (M0-M7)
* De novo or secondary disease
* Previously treated and refractory to prior therapy (which has included high-dose cytarabine and an anthracycline)
* Antecedent hematologic disorders allowed OR
* Histologically confirmed Philad... | 23,352 |
Study Objectives
This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body. The names of the study interventions involved in this study are:
* Cisplatin
* AZD1775
Conditions: Triple-negative Metastatic Breast Cancer
Int... | Inclusion Criteria:
* Participants must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease. Patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation.
* Either t... | 38,216 |
Study Objectives
This is a phase II intervention to propose a new melanoma chemoprevention agent. The investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in humans can be inferred by protection of nevi from ultraviolet light (UV)-induc... | Inclusion Criteria:
* Must have at least 2 nevi (each \>6 mm diameter) not clinically suspicious for melanoma that can be biopsied.
* Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines.
Exclusion Criteria:
* The patient is a minor (\< 18 y... | 15,481 |
Study Objectives
The goal of this study is to examine the effects of an enhanced caregiver training protocol that not only teaches informal caregivers knowledge and skills for managing patient symptoms, but also provides strategies for managing their own psychological distress. The investigators anticipate this trainin... | Inclusion Criteria (patients):
* Diagnosis of cancer (liquid or solid tumor);
* Admitted to DUMC's 9100 or 9300 for cancer treatment or related complications;
* 18 years of age or older;
* Able to read, speak and write in English;
* Anticipates being discharged to home;
* Not referred to hospice;
* Will have home care... | 8,343 |
Study Objectives
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the abil... | DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed colorectal carcinoma
* Metastatic disease
* Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as \> 20 mm by conventional techniques or \> 10 mm by spiral CT scan
* Brain m... | 5,960 |
Study Objectives
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Intervention / Treatment:
DRUG: MM-121, DRUG: Paclitaxel
Location: United States
Study Design and Phases
Study Type:... | Inclusion Criteria:
* Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
* Received at least one prior platinum based chemotherapy regimen
* Platinum-resistant or refractory
* Eligible for weekly paclitaxel
* Adequate liver and kidney function
* 18 ye... | 33,430 |
Study Objectives
This is a pilot trial to investigate the use of GM-CSF DNA as an adjuvant for peptide vaccination in patients with metastatic melanoma. The objective of this study is to determine the safety and adjuvant effect of vaccination with the gene coding for human GM-CSF with a multi-epitope melanoma peptide v... | Inclusion Criteria:
* Patients must have documented malignant melanoma, American Joint Commission on Cancer (AJCC) stage IIB, IIC, III or IV (54). Patients with resectable stage IIB, IIC and III disease must have undergone surgical resection before participating in this study.
* Patients with choroidal melanoma may pa... | 3,853 |
Study Objectives
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Conditions: Adult Anaplastic... | Inclusion Criteria:
* Histologically confirmed solid tumor, including gliomas and the following epithelial malignancies:
* Non-small cell lung
* Mesothelioma
* Breast
* Head and neck
* Esophageal
* Pancreatic
* Bladder
* Prostate
* Ovarian
* Anal
* Colorectal carcinoma
* Cervical carcinoma
*... | 43,392 |
Study Objectives
The purpose of this study is to develop and test a 6 month manualized Health Education intervention in recent breast cancer survivors.
Conditions: Breast Cancer
Intervention / Treatment:
BEHAVIORAL: Individualized Manualized Health Education Intervention
Location: United States
Study Design and Pha... | Inclusion Criteria:
* Female breast cancer survivor who is over 1 month and less than 24 months beyond the completion of primary therapy (surgery, radiation, and chemotherapy)
* Having received chemotherapy as part of their primary therapy for breast cancer
* Be in complete remission
* Aged 18 years or older
* Able to... | 18,861 |
Study Objectives
This study was a single-arm, open-label, phase II study of PD-1 monoclonal antibody combined with anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR uncommon mutations. Twenty-one patients of NSCLC harboring rare EGFR mutations after previous treatments, including a pla... | Inclusion Criteria:
1. Sign written informed consent before any trial-related processes are implemented;
2. Age ≥ 18 years old and ≤ 75 years old;
3. Life expectancy exceeds 3 months;
4. The investigator confirmed at least one measurable lesion according to the RECIST 1.1 standard. A measurable lesion located in the f... | 35,214 |
Study Objectives
This study is being done to study the healthful benefits of eating garlic. Previous studies suggest that garlic may help prevent cancer. The investigators are recruiting healthy volunteers to participate in a study to determine the ways in which eating garlic may reduce cancer risk.
Conditions: Health... | Inclusion Criteria:
* Age 40-80 years
Exclusion Criteria:
* Younger than 40 years old or older than 80 years old
* Use of blood-thinning medications such as Coumadin (warfarin), Dicumarol (dicumarol), or Miradon (anisinidione)
* Presence of kidney disease, liver disease, gout, certain cancers, thyroid disease, gastr... | 20,459 |
Study Objectives
Background:
- Irinotecan is a drug that is used to treat colon or rectal cancer. It affects the deoxyribonucleic acid (DNA) of growing cancer cells. It is most often used with other chemotherapy drugs. Researchers want to test it with an experimental drug, ISIS 183750. They want to see if the drugs ar... | * INCLUSION CRITERIA:
* Phase I: Patients must have histopathological confirmation of carcinoma by the Laboratory of Pathology of the National Cancer Institute (NCI) prior to entering this study.
* Phase II: Patients must have histopathological confirmation of Colorectal Carcinoma (CRC) by the Laboratory of Pathology o... | 42,835 |
Study Objectives
The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK in c... | Inclusion Criteria:
* A diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease.
* HER2 positive disease (3+ by immunohistochemistry \[IHC\] or FISH-positive)
* Candidate for treatment with trastuzumab. Prior treatment with trastuzumab and or/ lapatinib in the neoadjuva... | 13,295 |
Study Objectives
The purpose of this study is to assess the safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary neuroendocrine Tumors (NET).
Conditions: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreati... | Inclusion Criteria:
* Confirmed diagnosis of grade 1/2 advanced pulmonary or gastroenteropancreatic neuroendocrine tumor
* Progressive disease within last 12 months (only patients with nonfunctional tumors)
* Documented liver metastasis
* Measurable disease per RECIST determined by multiphase MRI or triphasic CT
Excl... | 38,996 |
Study Objectives
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC.
Specifically, researchers want to learn if standard SRT has as good of an outcome at 3 years after the procedure. The safety of the study treatment wi... | Inclusion Criteria:
1. Histological confirmation of non-small cell cancer will be required by either biopsy or cytology. The following primary cancer types are eligible: squamous cell carcinoma, adenocarcinoma with or without BAC features, large cell carcinoma with or without neuroendocrine features, neuroendocrine ca... | 5,172 |
Study Objectives
The main purpose of this study is to see how well FDG-PET scans can determine the malignancy of thyroid nodules that have already been tested (and come back positive) by fine needle aspiration.
Conditions: Thyroid Neoplasms
Intervention / Treatment:
OTHER: FDG-PET Scan
Location: United States
Study... | Inclusion Criteria:
* Documented history of a solitary thyroid nodule or a dominant nodule within multinodular disease, with fine needle aspiration demonstrating a follicular or indeterminate cytologic examination. If a core needle biopsy was performed instead of a fine needle aspiration, demonstrating follicular or i... | 44,764 |
Study Objectives
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.
The purpose of this study is to determine whether Clofarabine is sa... | Inclusion Criteria:
* Have a diagnosis of ALL according to FAB classification with greater than or equal to 25% blasts in the bone marrow.
* Be less than or equal to 21 years old at time of initial diagnosis.
* Not be eligible for therapy of higher curative potential, and must be in second or subsequent relapse and/or... | 2,295 |
Study Objectives
Study Design: This is a pragmatic study on the management strategy for patients with metastatic colorectal cancer (CRC) who are candidates for CT, independently of any previous adjuvant therapy received. The aim of this study is to define the role of new target molecules in combination with CT in first... | Inclusion Criteria:
1. Histologically or cytologically confirmed untreated metastatic or locally advanced, non resectable CRC; previous adjuvant chemotherapy for CRC or neoadjuvant/adjuvant chemoradiotherapy for rectal cancer is permitted but must have been completed at least 6 months prior to enrolment;
2. Resected C... | 10,284 |
Study Objectives
A study to evaluate effectiveness of sublobar dissection in patients with non-small cell lung cancer
Conditions: Non-small Cell Lung Cancer
Intervention / Treatment:
PROCEDURE: Sublobar dissection
Location: China
Study Design and Phases
Study Type: OBSERVATIONAL
Phase:
Primary Purpose:
Allocation... | Inclusion Criteria:
* Patients \>= 18 years old;
* Patients who received sublobar dissection from 2014 to 2017 (segment dissection/wedge dissection/segment and wedge dissections);
* Patients who received selective or systematic lymphadenectomy;
* Pathologically diagnosed patients with non-small cell lung cancer;
* Pat... | 23,087 |
Study Objectives
This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
Conditions: Acute Myeloid Leukemia
Intervention / Treatment:
DRUG: vosaroxin + cytarabine, DRUG: placebo + cytarabine
Location: Korea, Republic of, New Zealand,... | Inclusion Criteria:
* Provided signed, written informed consent
* At least 18 years of age
* Had a diagnosis of AML according to World Health Organization (WHO) classification
* First relapsed or refractory AML (refractory to initial induction therapy) with at least 5% blasts by bone marrow or aspirate or 1% blasts in... | 4,640 |
Study Objectives
Single -arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes.
Conditions: Recurrent Epithelial Ovarian Cancer
Intervention... | Inclusion Criteria:
* Histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer
* Recurrent ovarian cancer disease
* Signs for progression either measurable disease according to RECIST or CA 125 increase according the GCIG-criteria or clinical sympt... | 42,483 |
Study Objectives
The goal of this clinical research study is to find the highest tolerable dose of the combination of regorafenib and cetuximab that can be given to patients with advanced solid tumors. The safety and effectiveness of this drug combination will also be studied.
Conditions: Advanced Cancers
Interventio... | Inclusion Criteria:
1. Patient must be \>= 12 years of age and \> 40kgs.
2. Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that induces a CR rate of at least 10% or improves survival by at least three months.
3. Patients ... | 37,640 |
Study Objectives
The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab.
The secondary objectives are safety and pharmacokinetic interaction
Conditions: Breast Neoplasms
Intervention / Treatment:
DRUG: larotaxel (XRP9881), DRUG: trastuzumab
Location: Sweden, France, ... | Inclusion Criteria:
* Metastatic breast cancer (MBC)
* HER2 (Human Epidermal Growth Factor Receptor 2) positive: FISH (Fluorescent In Situ Hybridization) positive or IHC (Immunohistochemistry) 3+
* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)
* Adequate organs functions
Exclus... | 36,830 |
Study Objectives
Prospective study on patients with orbital tumors of unknown origin. Aim of the study is to differentiate benign from malignant tumors upon MR imaging. Magnetic resonance imaging of the orbit will be performed including standard morphological sequences and advanced sequence techniques. These advanced s... | Inclusion Criteria:
* non-diagnosed orbital tumors
Exclusion Criteria:
* any metal implants, non-MRI compatible
* age below 18
* pregnancy
* recent surgery
* recent severe medical diseases | 37,050 |
Study Objectives
The purpose of this research study is to learn if and in what amount a compound from hops, called xanthohumol (ZAN-tho-HUE-mol), prevents damage to DNA and oxidative stress. The human body is constantly exposed to oxidative stress from environmental compounds (e.g. air pollution) which may cause damage... | Inclusion Criteria:
* Non-smokers or no other tobacco use in the past 3 months.
* Willing to stop taking regular supplements including anti-oxidants for 2 weeks prior to study entry through conclusion of study.
* Willing to stop consumption of high levels of flavonoids and xanthohumol in the normal diet (onions, teas ... | 39,339 |
Study Objectives
Until recently, bolus 5-flourouracil (FU) + folinic acid (FA) has been considered the standard chemotherapy for patients with colorectal cancer. Several studies have shown that Capecitabine is as effective as Mayo regimen. The Nordic FU/FA schedule was developed to be an active and tolerable bolus regi... | Inclusion Criteria:
* Indication for treatment with a FU-regime
* WHO Performance Status 0-1
* Life expectancy \> 3 months
* Adequate haematological, renal and hepatic functions
* Adequate contraceptives
* Written informed consent
Exclusion Criteria:
* Known CNS-metastases
* Prior treatment with chemotherapy
* Pregn... | 19,034 |
Study Objectives
This phase Ⅱ study was designed to evaluate the efficacy and safety of FOLFIRI as second-line treatment for metastatic esophageal carcinoma.
Conditions: Advanced Esophageal Carcinoma
Intervention / Treatment:
DRUG: FOLFIRI
Location: China
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: PH... | Inclusion Criteria:
* Patients have provided a signed Informed Consent Form
* Karnofsky score ≥70
* Age: 18-75 years old
* Histologically confirmed diagnosis of advanced esophageal carcinoma
* Patients have Received and progressed on first-line treatment, and not received CPT-11 or Fluoropyrimidine based palliative ch... | 35,301 |
Study Objectives
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation therapy.
PURPOSE: Phase I trial to study the effectiveness of high-dose radia... | DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed non-small cell lung cancer
* Clinical stage T1-4, N0-2, M0
* Clinical stage T1-2, N0-1 must be medically inoperable
* No distant metastases on history and physical exam, CBC, screening profile, CT or MRI of brain, CT of chest and abdomen (inc... | 16,079 |
Study Objectives
Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in stage IV non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and ... | Inclusion Criteria:
Age ≥ 18 years.
Documented stage IV NSCLC, SCLC, BC or CRC (can be new diagnosis, persistent or recurrent disease):
BC patients who meet the following criteria:
ER+/HER2- and has failed hormone therapy within the last two years, or ER+/HER2+ or, ER-/HER+ or, HER2-/ER-/PR- (TNBC), and Has ≥ 1 mea... | 26,227 |
Study Objectives
Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced melanoma or metastatic TNBC
Safety: To characterize the safety of Imprime PGG + pembrolizumab given in combination
Hypothesis: Restore (for melanoma) or enhance (for TNBC) sensitivity to c... | Inclusion Criteria:
1. Have signed an informed document prior to any study-specific procedures or treatment
2. Be ≥ 18 years of age at time of consent
3. For Melanoma Subjects: Have histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic (Stage IV) melanoma not amenable to local the... | 17,846 |
Study Objectives
The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
Conditions: Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcin... | Inclusion Criteria:
* Biopsy proven, histological confirmed renal cell carcinoma (RCC) or renal medullary carcinoma (RMC).. Patients with surgery and biopsy at outside institutions will be eligible for this protocol once archival material is reviewed and the above diagnosis confirmed by genitourinary pathology review ... | 5,078 |
Study Objectives
CMP-001-007 is a Phase 2 study of CMP-001 intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed cell death protein 1 (PD-1) blocking antibody.
The primary objective of ... | Inclusion Criteria:
* Histologically- or cytologically-confirmed recurrent or metastatic HNSCC considered incurable by local therapies.
* No prior systemic therapy in the recurrent or metastatic setting. Systemic therapy as part of multi-modal treatment for locally advanced disease is allowed.
* Primary tumor location... | 40,580 |
Study Objectives
To assess the pharmacodynamics, safety/tolerability and efficacy of topical Omiganan (CLS001) in patients with usual type vulvar intraepithelial neoplasia (uVIN).
Conditions: Usual Type Vulval Intraepithelial Neoplasia (uVIN)
Intervention / Treatment:
DRUG: Omiganan (CLS001) topical gel, DRUG: Vehicl... | Inclusion Criteria:
1. Women ≥ 18 years
2. Biopsy proven uVIN, biopsies to have been taken within the last three months
3. Written informed consent to participate in the trial
4. At least one lesion that can be accurately measured (using RECIST criteria)
* in at least one dimension with longest diameter ≥ 20mm
... | 20,027 |
Study Objectives
RATIONALE: Quality-of-life assessment in patients undergoing cancer treatment may help determine the intermediate- and long-term effects of treatment on patients with cancer.
PURPOSE: This clinical trial studies the impact of therapy on the health status and quality of life of patients with stage I or... | DISEASE CHARACTERISTICS: Patients must be eligible for and registered to SWOG-9133
PATIENT CHARACTERISTICS: Patients must be able to complete the questionnaires in English. If they are not able to complete questionnaires in English, patients may be registered to SWOG-9133 without participating in SWOG-9208.
The Sympt... | 25,584 |
Study Objectives
Testing two different strategies for weight loss intervention and revealing possible changes in composition of gut microbiota, in order to provide more insight in the effect of dietary changes and weight loss treatments on gut microbiome in overweight and obese women with polycystic ovary syndrome (PCO... | Inclusion Criteria:
* PCOS according to ROtterdam criteria
* BMI ≥ 27 kg/m2 and at risk of metabolic syndrome or BMI ≥ 30 kg/m2
Exclusion Criteria:
* pregnancy
* pancreatitis (in the past)
* oral contraceptive pill use
* inflammatory bowel disease
* auto-immune disease
* immuno-modulatory drugs
* antidiabetic drugs
... | 30,611 |
Study Objectives
This study is an open label, multicenter phase 2 study. The primary objective of the study is to determine the efficacy of brentuximab vedotin in patients treated by gemcitabine for relapsed or refractory peripheral T-cell lymphoma in term of overall response rate assessed after 4 cycles of treatment a... | Inclusion Criteria:
* Males and females of 18 years to 80 years of age;
* Understand and voluntarily sign an informed consent document prior to any study related assessment or procedure;
* Patients able to adhere to the study visit schedule and protocol requirements;
* Patients with histologically proven, CD30 positiv... | 15,345 |
Study Objectives
This phase I trial is studying the side effects and best dose of tipifarnib and etoposide in treating older patients with newly diagnosed acute myeloid leukemia. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as et... | Inclusion Criteria:
* Adults age with established, pathologically confirmed diagnoses of newly diagnosed AML, including de novo and secondary AMLs but excluding newly diagnosed acute progranulocytic leukemia (APL, M3), will be considered eligible for study
* ECOG performance status 0-2
* Patient must be able to give i... | 38,236 |
Study Objectives
This is a randomized controlled trial that will evaluate the effectiveness of different reminder modalities for a population-based mailed FIT program at the VA Puget Sound among average risk Veterans who are due for annual colorectal cancer (CRC) screening.
Conditions: Colorectal Cancer
Intervention ... | Eligible participants are automatically enrolled in this project. We are unable to enroll participants upon request.
Inclusion Criteria:
* Veterans assigned to a primary care provider at the VA Puget Sound as of January 1, 2021
* At least 1 year of prior data available (evidence of at least one outpatient visit).
* D... | 40,107 |
Study Objectives
To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.
Conditions: Everolimus, Pneumonitis
Intervention / Treatment:
Location: China
Study Design and Phases
Study Type: OBSERVATIONAL
Phase:
Primary Purpose:
Allocation:
Interventional Model... | Inclusion Criteria:
1. Postmenopausal woman (or premenopausal women treated with LHRHa) diagnosed with HR+，HER2- metastatic breast cancer
2. Treated with everolimus for at least one month in metastatic setting
3. With baseline and at least one follow-up chest CT during everolimus therapy.
4. Complete medical history
... | 44,239 |
Study Objectives
All patients with a new, untreated solitary pulmonary nodule (SPN) between 7 mm and 3 cm in diameter identified by chest x-ray, will be approached to undergo positron emission tomography (PET) and computerized tomography (CT). The PET and CT scans will be interpreted independently.
The Primary Care Ph... | All patients with a new, untreated solitary pulmonary nodule (SPN) between 7 mm and 3 cm in diameter identified by chest x-ray, will be approached to participate in the study. | 4,974 |
Study Objectives
This research study is studying a combination of drugs with radiation as a possible treatment for Glioblastoma.
The drugs involved in this study are:
* Bavituximab
* Temozolomide
Conditions: Glioblastoma
Intervention / Treatment:
DRUG: Temozolomide, DRUG: Bavituximab, RADIATION: Radiation
Location... | Inclusion Criteria:
* Participants must have histologically confirmed newly diagnosed glioblastoma or glioblastoma variant (ex. gliosarcoma), including documentation of unmutated isocitrate dehydrogenase (IDH) by immunohistochemistry (sequencing not required).
* Participants must have 1-4 cm2 measurable disease (4 cm2... | 431 |
Study Objectives
This is a biomedical study of interventional type. The trial will include 270 patients (180 patients in the first cohort and 90 patients in a second cohort) over a period of 3 years + 2 years of follow up.
This prospective study will be conduct in patients who will receive a third line chemotherapy fo... | Inclusion Criteria:
1. Women of more than 18 years old
2. WHO 0-4
3. Metastatic breast cancer
4. Progression after two lines of chemotherapy with treatment decision by investigator to start a third-line chemotherapy
5. Evaluable disease
6. Histology: breast carcinoma whatever the histological type, grade, hormone rece... | 33,031 |
Study Objectives
We aim to develop an EUS-AI model which can facilitate clinical diagnosis by analyzing EUS pictures and clinical parameters of patients.
Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatitis, Chronic, Pancreatic Neuroendocrine Tumor, Autoimmune Pancreatitis
Intervention / Treatment:
DIAGNOSTIC_T... | Inclusion Criteria:
* Patients who underwent EUS using a curved line array echoendoscope (GF-UCT260; Olympus Medical Systems) since 2014 in our affiliation.
* For each patient, all available native EUS pictures are included.
* Patients' diagnosis are validated by surgical outcomes or fine-needle aspiration (FNA) findi... | 40,562 |
Study Objectives
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are unable to identify an acceptable unrelated HLA matched donor through the re... | Inclusion Criteria:
Eligible participants were assigned to one of two different strata dependent on diagnosis, disease status and/or past transplant experience. Both strata received the same intervention but will be followed and analyzed separately.
* Group A must have one of the following diagnosis
* Acute lympho... | 32,350 |
Study Objectives
Purpose:To gather preliminary data and to determine the feasibility and acceptability of an 8-week Tai Chi intervention for adults cancer survivors (survivors) who report experiencing cognitive impairment, and to perform exploratory analyses to assess improvements in cognitive performance, health-relat... | Inclusion Criteria:
* Was diagnosed with breast cancer (all stages accepted).
* Currently \> 18 years of age
* Age at cancer diagnosis \> 18 years.
* Able to engage in moderate intensity exercise as determined by their treating physician. If participant no longer has a treating physician, safety will be determined by ... | 31,321 |
Study Objectives
This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.
Conditions: Refractory Leukemia, Acute Myelogenous Leukemia
Intervention / Treatment:
DRUG: Panobinostat/LBH589
Location: Korea, Republic of, Belg... | Inclusion Criteria:
* Written informed consent prior to study-specific screening procedures
* Life expectancy of ≥ 60 days
* Eastern Cooperative Group (ECOG) performance status ≤ 2
* Refractory AML with confirmed initial diagnosis of de novo AML (excluding APL) - OR- Refractory AML with confirmed initial diagnosis of ... | 8,313 |
Study Objectives
RATIONALE: Comparing lung CT scans from participants with lung nodules at high-risk for lung cancer may help doctors learn more about the disease and find better methods of treatment.
PURPOSE: This trial studies the natural history of lung nodules using CT scans from participants at high-risk for lung... | DISEASE CHARACTERISTICS:
* Annual Computed Tomography (CT) scans obtained from participants with undetermined lung nodules detected by low-dose CT enrolled in both of the following trials:
* A large-scale COSMOS screening trial
* Three annual CT scans obtained as part of the COSMOS trial after budesonide study... | 28,252 |
Study Objectives
This is a randomized, multicenter, open-label, two-arm study in treatment-naive participants with operable, locally advanced, or inflammatory, centrally-assessed HER2-positive early breast cancer (EBC) whose primary tumors were greater than or equal to (\>/=) 2 centimeters (cm). The study was designed ... | Inclusion Criteria:
* Histologically confirmed invasive breast cancer with a primary tumor size of greater than (\>) 2 cm
* HER2-positive breast cancer
* Participants with multifocal tumors (more than one tumor confined to the same quadrant as the primary tumor) are eligible provided all discrete lesions are sampled a... | 6,324 |
Study Objectives
The main aim of the study is to assess if a pre consultation intervention facilitates greater participation of patients (and accompanying key persons when present) in the consultation process by determining an increase in questioning and/or in the number of different illness related issues (e.g. diagno... | Inclusion Criteria:
* all consecutive patients
* age between 18 and 75 years
* attending the Oncology Out-patient Clinics of the participating centres
* recent diagnosis of breast cancer at an early stage
Exclusion Criteria:
* presence of metastasis or relapse
* severe mental deterioration
* comprehension difficulti... | 16,325 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 3